stockrowCharles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.
- Revenue
- −2.20%
- EPS
- +530.3%
- Free cash flow
- +16.3%
- Total debt
- +11.8%
Quarter to September 2026, against a year earlier
Follow CRL
Alert me
Charles River Laboratories International, Inc. (CRL) Revenue
Charles River Laboratories International, Inc.'s revenue for fiscal 2025 was $4.0B, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $4.0B. Over the past ten years it has ranged from $1.4B (fiscal 2015) to $4.1B (fiscal 2023); the current reading is higher than 82% of that period. Charles River Laboratories International, Inc. ranks 12th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.0B | (0.85%) |
| FY2024 | $4.0B | (1.92%) |
| FY2023 | $4.1B | 3.86% |
| FY2022 | $4.0B | 12.31% |
| FY2021 | $3.5B | 21.08% |
| FY2020 | $2.9B | 11.55% |
| FY2019 | $2.6B | 15.67% |
| FY2018 | $2.3B | 21.99% |
| FY2017 | $1.9B | 10.48% |
| FY2016 | $1.7B | 23.34% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $982.7M | (2.13%) |
| Jun 2026 | $1.0B | 0.83% |
| Mar 2026 | $995.8M | 0.16% |
| Dec 2025 | $994.2M | (1.06%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.6B |
| DGX Quest Diagnostics Incorporated compare | $11.8B |
| ICLR ICON PLC compare | $8.2B |
| ILMN Illumina, Inc. compare | $4.5B |
| CRL Charles River Laboratories International, Inc. | $4.0B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| QGEN QIAGEN N.V. compare | $2.1B |
| GH Guardant Health, Inc. compare | $1.3B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CRL
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement